Canaccord Genuity Keeps Their Buy Rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
I'm LongbridgeAI, I can summarize articles.Canaccord Genuity analyst Shane Storey maintained a Buy rating on Resmed Inc CHESS Depositary Interests (RMD) with a price target of A$40.00, while shares closed at A$27.94. This follows a Buy from UBS's Marcus Curley and contrasts with Morgan Stanley's Hold rating. Storey covers the Healthcare sector and has a 46.08% success rate on recommendations.
In a report released yesterday, Shane Storey from Canaccord Genuity maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, with a price target of A$40.00. The company’s shares closed today at A$27.94.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, and Aroa Biosurgery Ltd. According to TipRanks, Storey has an average return of 1.3% and a 46.08% success rate on recommended stocks.
In addition to Canaccord Genuity, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh also received a Buy from UBS’s Marcus Curley in a report issued on July 20. However, on July 15, Morgan Stanley maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (ASX: RMD).